NASDAQ, NBIX - Neurocrine Bioscienc
We were originally incorporated in California in January 1992 and were
reincorporated in Delaware in May 1996.
We discover, develop and intend to commercialize drugs for the treatment of
neurological and endocrine-related diseases and disorders. Our product
candidates address some of the largest pharmaceutical markets in the world,
including endometriosis, irritable bowel syndrome, anxiety, depression, pain,
diabetes, insomnia, and other neurological and endocrine related diseases and
disorders. We currently have eight programs in various stages of research and
development, including five programs in clinical development. While we
independently develop many of our product candidates, we have entered into a
collaboration for two of our programs. ...
Read SEC Filing on NASDAQ.com »